4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide has been researched along with pd 98059 in 1 studies
| Studies (4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide) | Trials (4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide) | Recent Studies (post-2010) (4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide) | Studies (pd 98059) | Trials (pd 98059) | Recent Studies (post-2010) (pd 98059) |
|---|---|---|---|---|---|
| 62 | 0 | 14 | 4,939 | 3 | 1,001 |
| Protein | Taxonomy | 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide (IC50) | pd 98059 (IC50) |
|---|---|---|---|
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 2.8 | |
| Luciferin 4-monooxygenase | Photinus pyralis (common eastern firefly) | 6.3 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 2.8 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 1 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 2.8 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Rattus norvegicus (Norway rat) | 4.2 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Rattus norvegicus (Norway rat) | 4.2 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harada, N; Mawatari, K; Nakamura, A; Nakano, M; Nakaya, Y; Takahashi, A; Tsutsumi, K | 1 |
1 other study(ies) available for 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide and pd 98059
| Article | Year |
|---|---|
NO-1886, a lipoprotein lipase activator, attenuates vascular smooth muscle contraction in rat aorta.
Topics: Adrenergic alpha-Agonists; Animals; Aorta, Thoracic; Benzamides; Calcium; Calcium Channel Blockers; Calcium Channels, N-Type; Calcium-Calmodulin-Dependent Protein Kinases; Dose-Response Relationship, Drug; Enzyme Activators; Flavonoids; Hypolipidemic Agents; In Vitro Techniques; Lipoprotein Lipase; Male; Muscle Contraction; Muscle, Smooth, Vascular; Organophosphorus Compounds; Phenylephrine; Potassium Chloride; Protein Kinase C; Rats; Rats, Wistar; Signal Transduction; Staurosporine; Vasoconstriction; Vasodilation; Verapamil | 2007 |